Humanin (Humanin (HN) Mitochondrial-Derived Peptide)
A 24-amino acid mitochondria-derived peptide with cytoprotective effects against Alzheimer toxicity, oxidative stress, and apoptosis. Levels decline significantly with age.
How it works
Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection.
Key facts
- Molecular weight: 2,687 Da
- Half-life: 4-6 hours
- Bioavailability: Moderate (SubQ)
- Storage: Lyophilized: -20°C. Reconstituted: 2-8°C.
Dosing overview
- Typical dose: 1-5 mg
- Frequency: 3-5x per week
- Duration: 8-12 weeks
- Route: Subcutaneous
Reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
Possible side effects
- Injection site reactions
- Mild fatigue (initial)
- Limited human safety data
Research
- Humanin levels decline with age and correlate with cognition (2022): Circulating humanin decreased 40% between ages 20-80, correlating with worse cognitive performance.
- Cytoprotective mechanisms against amyloid-beta (2021): Prevented AB-induced neuronal death by 70% through BAX inhibition and caspase-3 blockade.
Compare Humanin
Community discussions about Humanin
- Adding Humanin to my KLOW protocol – thoughts on dosing and timing? - 4 comments
- Ask the community about Humanin
Research and educational reference only. Not medical advice.